This podcast series will highlight the recommended approach to managing patients with peripheral arterial disease from screening to therapy selection. Appropriate risk factor modification and therapy is essential in PAD to optimize care by reducing cardiovascular morbidity and mortality.
SPEAKERS
Zachary Stacy, Pharm.D., BCPS, FCCP, is a clinical pharmacist at the Barnes Jewish West County Hospital. Dr. Stacy earned his Bachelor of Science degrees in Chemistry and Biology from Blackburn College in Carlinville, Illinois, and his Master of Science degree in Chemistry from Southern Illinois University in Edwardsville, Illinois. Dr. Stacy completed his Doctor of Pharmacy degree at the St. Louis College of Pharmacy and a specialty residency in internal medicine at St. Luke’s Hospital in Chesterfield, Missouri.
Dr. Stacy’s primary research interests include the prevention of venous thromboembolism and the management of peripheral arterial disease. Dr. Stacy’s didactic responsibilities include ischemic heart disease, heart failure, peripheral arterial disease, and venous thromboembolism. He teaches in the Physician Assistant program at Saint Louis University and the Dental Hygienist program at St. Louis Community College.
Dr. Stacy has won numerous teaching awards including the 2005 Excellence in Clinical Precepting, the 2009 Joe E. Haberle Outstanding Educator of the Year Award, 2009 Emerson Excellence in Teaching Award, and the 2010 Missouri Pharmacy Association Faculty Member of the Year Award. He has authored numerous articles, reviews, and book chapters and frequently provides presentations at state, national, and international conferences. He is an active member of numerous pharmacy organizations including ACCP and ASHP. In 2013, Dr. Stacy was named a Fellow of the American College of Clinical Pharmacy.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company.
Toby C. Trujillo, Pharm.D., FCCP, FAHA, BCPS-AQ Cardiology, is Associate Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Trujillo also serves as Clinical Specialist in cardiovascular pharmacotherapy and anticoagulation at University of Colorado Hospital in Aurora, Colorado.
Dr. Trujillo earned his Bachelor of Science degree in biochemistry from the University of California, Davis and his Doctor of Pharmacy degree from the University of California, San Francisco, where he also completed a residency in pharmacy practice. Dr. Trujillo completed a fellowship in cardiovascular pharmacotherapy at The University of Arizona, and he is a board-certified pharmacotherapy specialist with added qualifications in cardiology.
In his current role, Dr. Trujillo is involved in the stewardship of antithrombotic medications across the UC Health System, which includes serving as co-chair of the anticoagulation subcommittee of the P&T committee, as well as coordinating and staffing the Inpatient-Anticoagulation Thrombosis Management Service.
Dr. Trujillo has served in several capacities within multidisciplinary organizations such as the American Heart Association, American College of Cardiology, and the Society of Critical Care Medicine. Dr. Trujillo has also served a number of committees and leadership positions within the American College of Clinical Pharmacy including the Board of Regents. Dr. Trujillo has served as a speaker on numerous occasions on a national and international level, and has published over 80 original research articles, review articles, and book chapters dealing with the area of cardiovascular pharmacotherapy. His research interests primarily focus on the appropriate use of antithrombotic medications, both at the patient and health-system level.
Relevant Financial Relationship Disclosure
No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company
This podcast is provided by ASHP and sponsored by Janssen Pharmaceuticals, Inc.
